...A. And in fact, cash flow positive on an annual basis. B. In fact, we've just announced that in our first quarter, we had a quarter of $78.9 million for the quarter and in fact, increased our guidance for the year to $370 million to $390 million. C. And that, at the midpoint, represents roughly 63% year-over-year growth since last year. D. But on top of that, we're also looking at growth, obviously, from the rest of the pipeline, we have announced that we're moving our abiprubart molecule, which is a CD40-CD154 molecule into Phase II. E. We've had some successful deals done with vixarelimab was a IL-31 and oncostatin M molecule that we out-licensed in Roche/Genentech and that was around $125 million plus royalties and milestones. F. And we are looking to monetize our mavrilimumab molecule. G. This is an anti-GM-CSF molecule that we took through Phase II in a number of positive indication....
